Clinical Research Directory
Browse clinical research sites, groups, and studies.
Hepatocellular Carcinoma Identification Using Delta-HLD
Sponsor: Epiliquid Holding, Inc
Summary
HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.
Official title: Proof-of-Concept Case-Control Study for Hepatocellular Carcinoma Identification Using Delta-HLD Technology (HIDE)
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2023-05-18
Completion Date
2026-12
Last Updated
2025-09-09
Healthy Volunteers
No
Conditions
Locations (1)
Epiliquid
Mendoza, Argentina